SALT LAKE CITY, May 14, 2019 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has…Original Article
Lipocine Announces Tlando NDA PDUFA Action Date of November 9, 2019
